{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:06:30Z","timestamp":1782108390106,"version":"3.54.5"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Covalent Bruton tyrosine kinase inhibitor (cBTKi)\u2010based regimens have redefined therapy for chronic lymphocytic leukemia (CLL). However, continuous treatment with BTKis can select for therapy resistance, typically associated with\n                    <jats:italic>BTK C481<\/jats:italic>\n                    mutations and fosfolipasi C gamma 2 (PLC\u03b32) activation. In addition, continuous BTKi therapy poses challenges for treatment interruptions and dose modifications, with implications for clinical outcomes. Pirtobrutinib, a highly selective, reversible (noncovalent) BTKi, inhibits BTK independently of C481 and maintains sustained target engagement. In patients with cBTKi\u2010pretreated relapsed\/refractory (R\/R) CLL, the BRUIN\u2010CLL\u2010321 trial demonstrated improved progression\u2010free survival (PFS) and time to next treatment (TTNT) compared with idelalisib\/rituximab or bendamustine\/rituximab, accompanied by a favorable tolerability profile. Data from randomized phase III BRUIN\u2010CLL\u2010313 and BRUIN\u2010CLL\u2010314 trials demonstrate the superiority of pirtobrutinib over chemoimmunotherapy in untreated patients and non\u2010inferiority to ibrutinib in untreated patients or in patients with R\/R disease who had no prior exposure to cBTKis. These data are not sufficient to justify a change in clinical practice; however, they lay the groundwork for a potential future repositioning of pirtobrutinib from the treatment of R\/R CLL to earlier lines of therapy. In this review, we address a range of current and prospective aspects of pirtobrutinib\u2010based therapies: (1) the strengths and limitations of the trial datasets; (2) the biological rationale for frontline noncovalent BTK inhibition; (3) sequencing trade\u2010offs; and (4) prospective scenarios, including combination strategies and time\u2010limited regimens.\n                  <\/jats:p>","DOI":"10.1111\/ejh.70160","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:54:44Z","timestamp":1773366884000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (\n                    <scp>CLL<\/scp>\n                    ) Care"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6507","authenticated-orcid":false,"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Hull York Medical School University of Hull  Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6109","authenticated-orcid":false,"given":"David","family":"Allsup","sequence":"additional","affiliation":[{"name":"Centre for Biomedicine Hull York Medical School  Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028205"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02265"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012221"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2256911"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2466101"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.053"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27544"},{"key":"e_1_2_11_19_1","first-page":"62","article-title":"Preclinical Characterization of Pirtobrutinib, a Highly Selective, Noncovalent (Reversible) BTK Inhibitor","volume":"142","author":"Gomez E. B.","year":"2023","journal-title":"Blood"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203434"},{"key":"e_1_2_11_21_1","first-page":"3137","article-title":"Pirtobrutinib: A New Hope for Patients With BTK Inhibitor\u2010Refractory Lymphoproliferative Disorders","volume":"141","author":"Thompson P. A.","year":"2023","journal-title":"Blood"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_2_11_24_1","first-page":"92","article-title":"Pirtobrutinib Monotherapy in Bruton Tyrosine Kinase Inhibitor\u2010Intolerant Patients With B\u2010Cell Malignancies: Results of the Phase I\/II BRUIN Trial","volume":"110","author":"Shah N. N.","year":"2025","journal-title":"Haematologica"},{"key":"e_1_2_11_25_1","article-title":"Pharmacological Profiling in CLL Patients During Pirtobrutinib Therapy and Disease Progression","volume":"3","author":"Gandhi V.","year":"2025","journal-title":"Research Square"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182974"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201002380"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201002477"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027009"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031598"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026672"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00166"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01695"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15802"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30909\u20109"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(24)00070\u20106"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201002691"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024510"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-680"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145920"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281402"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5684"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001382\u2010x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2567834"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:54:03Z","timestamp":1781873643000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/ejh.70160"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70160","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2026-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}